As BEZ235 exhibits multifaceted anti-tumor activities in part by suppressing vascular endothelial growth factor-dependent angiogenesis,32 further study of this combination strategy in ovarian cancer is warranted to determine whether greater anti-angiogenic and anti-tumor effects could be achieved. This evidence concerns the gene VEGFA and ovarian carcinoma.